Skip to main content
main-content

07.01.2016 | Original Article | Ausgabe 7/2016

Tumor Biology 7/2016

Neferine induces autophagy of human ovarian cancer cells via p38 MAPK/ JNK activation

Zeitschrift:
Tumor Biology > Ausgabe 7/2016
Autoren:
Limei Xu, Xiyu Zhang, Yinuo Li, Shuhua Lu, Shan Lu, Jieyin Li, Yuqiong Wang, Xiaoxue Tian, Jian-jun Wei, Changshun Shao, Zhaojian Liu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13277-015-4737-8) contains supplementary material, which is available to authorized users.

Abstract

Ovarian cancer is the most lethal gynecological malignancy. Patients usually have poor prognosis because of late diagnosis, relapse, and chemoresistance. It is pressing to seek novel agent for the treatment of ovarian cancer. Neferine is a bisbenzylisoquinoline alkaloid isolated from the embryos of lotus (Nelumbo nucifera). In this study, we investigated the antitumor effect of neferine on ovarian cancer cells. We found that neferine exhibited growth-inhibitory effect on human ovarian cancer cells, whereas showing less cytotoxic to non-malignant fallopian tube epithelial cells. Furthermore, we demonstrated that neferine induced autophagy and inactivated the mTOR pathway. Finally, we found that both p38 MAPK and JNK signaling pathways were activated by neferine treatment and contributed to the induction of autophagy in ovarian cancer cells. In conclusion, our findings showed that neferine induced autophagy of human ovarian cancer cells via p38 MAPK/JNK activation. Neferine may be explored as a promising antitumoral agent in ovarian cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
ESM 1 (GIF 56 kb)
13277_2015_4737_MOESM1_ESM.gif
ESM 2 (GIF 42 kb)
13277_2015_4737_MOESM2_ESM.gif
ESM 3 (DOCX 12 kb)
13277_2015_4737_MOESM3_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.